Cost Effectiveness Analysis of Filgrastim versus Placebo in Post AIIogentic Bone Marrow Transplantation  

作　　者：Maoudoud Ines Razgallah Khrouf Myriam Ben Abdejelil Nour Ghedira Hela Amel Lakhal Marsit Hanene Turki Manel Soussi Mohamed Ali Lazreg Olfa Ladab Saloua Ben Othmane Tarek 

机构地区：[1]University of Monastir, Faculty of Pharmacy-5000 Tunisia [2]Centre National de Greffe de Moelle Osseuse-1006 Tunisia [3]University of Tunis El Manar, Faculty of Medicine of Tunis-1006 Tunisia

出　　处：《Journal of Pharmacy and Pharmacology》2016年第6期268-272,共5页药剂与药理学（英文版）

摘　　要：Filgrastim is used to accelerate hematopoietic recovery after ABMT （allogeneic bone marrow transplantation）. Its impact on the total cost of patient care remains to be explored. We therefore undertook a cost effectiveness analysis in the context of a randomized single blinded clinical trial of Filgrastim versus placebo in post ABMT. A primary endpoint, duration of myelosuppression, and three secondary end points （number of days of fever, length of hospital stay, survival at one hundred days） were used to assess efficacy. Direct costs were evaluated and allowed the calculation of the ICER （incremental cost-effectiveness ratios） for the major endpoint of the trial. Sixteen patients were included in the study. The duration of myelosuppression was significantly decreased in the Filgrastim arm with medians of 15 days vs. 19 days in the placebo arm （p = 0.023）. Cost analysis showed no statistically significant difference between the two arms. According to the calculation of ICER, Filgrastim was more costly and more effective than placebo for the number of days of aplasia avoided and the number of days with fever avoided. Placebo strictly dominated filgrastim for days of hospitalization avoided. Filgrastim has proven effective in reducing the duration of aplasia without increasing costs.

关 键 词：FILGRASTIM PLACEBO COST EFFECTIVENESS allogeneic bone marrow transplantation. 

分 类 号：S858.31[农业科学—临床兽医学] TU246.11[农业科学—兽医学]